Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0

A Proportional Hazards Model for the Subdistribution of a Competing Risk

Jason P. Fine · Journal of the American Statistical Association · 1999 · 13.6K citations

Public Health, Biostatistics, Cost-effectiveness Analysis +15

Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study

Kimme L Hyrich, Mark Lunt, Kath Watson et al. · Arthritis & Rheumatism · 2006 · 403 citations

Medicine, Pharmacology, Pharmacotherapy +13

A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview

Jasvinder A. Singh, Robin Christensen, George A. Wells et al. · Canadian Medical Association Journal · 2009 · 230 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +17

Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register

Moetaza M. Soliman, Darren M. Ashcroft, Kath Watson et al. · Annals of the Rheumatic Diseases · 2011 · 220 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +16

Comparison of drug retention rates and causes of drug discontinuation between anti–tumor necrosis factor agents in rheumatoid arthritis

Sophie Martin Du Pan, Silvia Dehler, Adrian Ciurea et al. · Arthritis Care & Research · 2009 · 210 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13